319 related articles for article (PubMed ID: 18615708)
1. CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Gopaluni S; Perzova R; Abbott L; Farah R; Shrimpton A; Hutchison R; Poiesz BJ
Am J Hematol; 2008 Sep; 83(9):744-6. PubMed ID: 18615708
[TBL] [Abstract][Full Text] [Related]
2. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
3. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
4. Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene.
Mehlmauer MA
Cutis; 2004 Jun; 73(6):417-20. PubMed ID: 15224787
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
6. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
7. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
8. Poikilodermatous mycosis fungoides.
Farley-Loftus R; Mandal R; Latkowski JA
Dermatol Online J; 2010 Nov; 16(11):8. PubMed ID: 21163159
[TBL] [Abstract][Full Text] [Related]
9. [Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma].
Rodriguez Suarez S; Pamies Andreu E; Muñiz Grijalvo O; Garcia Morillo JS
Med Clin (Barc); 2016 Feb; 146(3):117-20. PubMed ID: 26688184
[TBL] [Abstract][Full Text] [Related]
10. Juvenile mycosis fungoides treated with bexarotene and PUVA.
Rodríguez-Vázquez M; García-Arpa M; González-García J
Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
[TBL] [Abstract][Full Text] [Related]
11. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
12. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene monotherapy for epidermotropic CD8+ CTCL.
Kamstrup M; Gniadecki R
Dermatol Clin; 2008 Jan; 26 Suppl 1():45-7. PubMed ID: 18405187
[No Abstract] [Full Text] [Related]
14. Treatment of refractory stage IV mycosis fungoides with bexarotene monotherapy.
Otremba B
Dermatol Clin; 2008 Jan; 26 Suppl 1():51-2. PubMed ID: 18405188
[No Abstract] [Full Text] [Related]
15. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
McGinnis KS; Junkins-Hopkins JM; Crawford G; Shapiro M; Rook AH; Vittorio CC
J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
[TBL] [Abstract][Full Text] [Related]
16. Bexarotene monotherapy for patients with advanced stage mycosis fungoides.
Bachelez H
Dermatol Clin; 2008 Jan; 26 Suppl 1():25-6. PubMed ID: 18405183
[No Abstract] [Full Text] [Related]
17. Folliculotropic mycosis fungoides responding to bexarotene gel.
Walling HW; Swick BL; Gerami P; Scupham RK
J Drugs Dermatol; 2008 Feb; 7(2):169-71. PubMed ID: 18335654
[TBL] [Abstract][Full Text] [Related]
18. Acitretin for the treatment of cutaneous T-cell lymphoma.
Cheeley J; Sahn RE; DeLong LK; Parker SR
J Am Acad Dermatol; 2013 Feb; 68(2):247-54. PubMed ID: 22917895
[TBL] [Abstract][Full Text] [Related]
19. Bexarotene monotherapy for patients with refractory early stage mycosis fungoides.
Stein A
Dermatol Clin; 2008 Jan; 26 Suppl 1():67-70. PubMed ID: 18405191
[No Abstract] [Full Text] [Related]
20. Bexarotene plus PUVA plus radiation combination therapy for mycosis fungoides.
Coors E
Dermatol Clin; 2008 Jan; 26 Suppl 1():33-5. PubMed ID: 18405185
[No Abstract] [Full Text] [Related]
[Next] [New Search]
